Moderna to reveal late-breaking data on flu & RSV mRNA vax at ESCMID 2026

The data will be presented at the 2026 European Society of Clinical Microbiology and Infectious Diseases (ESCMID) Global Congress in Munich, April 17-21

ImmunityBio responds to FDA concerns over promotional content

Apnimed secures $150 million financing to fuel US launch of oral sleep apnea drug AD109

The financing includes a four-year interest-only period, extendable to five years if a net sales milestone is achieved

Aurobindo Pharma’s CuraTeQ achieves Phase 3 success for Omalizumab biosimilar

The drug meets all primary endpoints across 608 patients in Europe and India, strengthening the company's biosimilars pipeline

Enveda’s experimental oral therapy shows breakthrough results in atopic dermatitis trial

Safety was equally impressive. ENV-294 was well tolerated

Nuvation Bio secures global rights to promising brain tumor drug Safusidenib, expands Phase 3 study to Japan

Agenus launches landmark global Phase 3 trial in hard-to-treat colorectal cancer

The study targets patients with refractory, unresectable microsatellite-stable (MSS)/mismatch repair proficient (pMMR) metastatic colorectal cancer (mCRC)

Cardinal Health boosts production of cutting-edge cancer therapy ingredient

Ac-225, an alpha-emitting radionuclide, can be paired with molecules designed to selectively target cancer cells.

Torqur taps Lonza to power late-stage push for skin cancer therapy

Lonza will take on technology transfer, process optimization, and cGMP manufacturing, leveraging its global network and expertise in highly potent compounds

Biocytogen partner NEOK Bio gets FDA nod for novel cancer therapy

The investigational new drug application with FDA was actually for NEOK002, an EGFR/MUC1-targeting antibody-drug conjugate aimed at solid tumors